Gene activation of CEBPA using saRNA: Preclinical studies of the first in human saRNA drug candidate for liver cancer

Oncogene

Volumn 37, Issue 24, 2018, Pages 3216-3228

  Reebye, Vikash ^a   Huang, Kai Wen ^b   Lin, Vivian ^b   Jarvis, Sheba ^a   Cutilas, Pedro ^c   Dorman, Stephanie ^a   Ciriello, Simona ^d   Andrikakou, Pinelopi ^a   Voutila, Jon ^d   Saetrom, Pal ^e   Mintz, Paul J ^a   Reccia, Isabella ^a   Rossi, John J ^f   Huber, Hans ^g   Habib, Robert ^d   Kostomitsopoulos, Nikos ^h   Blakey, David C ^d   Habib, Nagy A ^a  

^a IMPERIAL COLLEGE LONDON   (United Kingdom)

^b NATIONAL TAIWAN UNIVERSITY   (Taiwan)

^c QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

^d MiNA Therapeutics Ltd   (United Kingdom)

^e NORWEGIAN UNIVERSITY OF SCIENCE AND TECHNOLOGY   (Norway)

^f CITY OF HOPE NATIONAL MEDICAL CENTER   (United States)

^g BioTD Strategies LLC   (United States)

^h BIOMEDICAL RESEARCH FOUNDATION   (Greece)

Author keywords

[No Author keywords available]

Indexed keywords

CCAAT ENHANCER BINDING PROTEIN ALPHA SMALL ACTIVATING RNA; LIPOSOME; RNA; UNCLASSIFIED DRUG; CCAAT ENHANCER BINDING PROTEIN; CEBPA PROTEIN, HUMAN; DIETHYLNITROSAMINE; SMALL UNTRANSLATED RNA;

ADOLESCENT; ADULT; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CARBON TETRACHLORIDE-INDUCED LIVER FIBROSIS; CONTROLLED STUDY; FATTY LIVER; GENE ACTIVATION; HEP-G2 CELL LINE; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; K-9 CELL LINE; LIPOSOMAL GENE DELIVERY SYSTEM; LIVER CELL; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; LIVER FUNCTION; MALE; MOUSE; NONHUMAN; OLIGONUCLEOTIDE THERAPY; PRECLINICAL STUDY; PRIORITY JOURNAL; RAT; REAL TIME POLYMERASE CHAIN REACTION; SURVIVAL RATE; TUMOR VOLUME; WESTERN BLOTTING; WISTAR RAT; ANIMAL; C57BL MOUSE; CHEMICALLY INDUCED; END STAGE LIVER DISEASE; EXPERIMENTAL LIVER CIRRHOSIS; EXPERIMENTAL LIVER NEOPLASM; GENE EXPRESSION REGULATION; GENE THERAPY; GENETICS; MIDDLE AGED; NONALCOHOLIC FATTY LIVER; PROCEDURES; SPRAGUE DAWLEY RAT; TRANSCRIPTION INITIATION; TRANSGENIC MOUSE;

ANIMALS; CCAAT-ENHANCER-BINDING PROTEINS; DIETHYLNITROSAMINE; END STAGE LIVER DISEASE; GENE EXPRESSION REGULATION, NEOPLASTIC; GENETIC THERAPY; HEP G2 CELLS; HUMANS; LIVER CIRRHOSIS, EXPERIMENTAL; LIVER NEOPLASMS, EXPERIMENTAL; MALE; MICE, INBRED C57BL; MICE, TRANSGENIC; MIDDLE AGED; NON-ALCOHOLIC FATTY LIVER DISEASE; RATS, SPRAGUE-DAWLEY; RATS, WISTAR; RNA, SMALL UNTRANSLATED; TRANSCRIPTIONAL ACTIVATION;

EID: 85042877246     PISSN: 09509232     EISSN: 14765594     Source Type: Journal    
DOI: 10.1038/s41388-018-0126-2     Document Type: Article

References (22)

1. Ge PS, Runyon BA. Treatment of patients with cirrhosis. N Engl J Med. 2016;375:767-77.
2. Allen AM, Kim WR, Moriarty JP, Shah ND, Larson JJ, Kamath PS. Time trends in the health care burden and mortality of acute on chronic liver failure in the United States. Hepatology. 2016;64:2165-72.
3. Starley BQ, Calcagno CJ, Harrison SA. Nonalcoholic fatty liver disease and hepatocellular carcinoma: a weighty connection. Hepatology. 2010;51:1820-32.
4. Ekstedt M, Hagström H, Nasr P, Fredrikson M, Stål P, Kechagias S. et al. Fibrosis stage is the strongest predictor for disease-specific mortality in NAFLD after up to 33 years of follow-up. Hepatology. 2015;61:1547-54.
5. Portnoy V, Huang V, Place RF, Li LC. Small RNA and transcriptional upregulation. WIREs RNA. 2011;2:748-60.
6. Portnoy V, Lin SHS, Li KH, Burlingame A, Hu Z-H, Li H, et al. saRNA-guided Ago2 targets the RITA complex to promoters to stimulate transcription. Cell Res. 2016;26:320-35.
7. Mei S, Wang X, Zhang J, Qian J, Ji J. In vivo transfection of C/EBP-alpha gene could ameliorate CCL(4)-induced hepatic fibrosis in mice. Hepatol Res. 2007;37:531-9.
8. Tao L-L, Cheng Y-Y, Ding D, Mei S, Xu J-W, Yu J, et al. C/EBP-α ameliorates CCl(4)-induced liver fibrosis in mice through promoting apoptosis of hepatic stellate cells with little apoptotic effect on hepatocytes in vitro and in vivo. Apoptosis. 2012;17:492-502.
9. Hong I-H, Lewis K, Iakova P, Jin J, Sullivan E, Jawanmardi N, et al. Age-associated change of C/EBP family proteins causes severe liver injury and acceleration of liver proliferation after CCl4 treatments. J Biol Chem. 2014;289:1106-8.
10. Ee HT, Shing CH, Mirtha L, Esther W, Sathivel P, Aileen W. et al. CAAT/enhancer binding protein alpha knock-in mice exhibit early liver glycogen storage and reduced susceptibility to hepatocellular carcinoma. Cancer Res.2005;65:10330-7.
11. Shi Y-C, Zhao H, Yin C, Zeng X, Zhang Q, Xu W-P, et al. C/EBPα inhibits hepatocellular carcinoma by reducing Notch3/Hes1/p27 cascades. Dig Liver Dis. 2013;45:844-51.
12. Reebye V, Sætrom P, Mintz PJ, Huang K-W, Swiderski P, Peng L, et al. Novel RNA oligonucleotide improves liver function and inhibits liver carcinogenesis in vivo. Hepatology. 2014;59:216-27.
13. Voutila J, Reebye V, Roberts TC, Protopapa P, Andrikakou P, Blakey DC et al. Development and mechanism of small activating RNA targeting CEBPA, a novel therapeutic in clinical trials for liver cancer. Mol Ther 2017;25:2705-14.
14. Rodrigueza WV, Woolliscroft MJ, Ebrahim A-S, Forgey R, McGovren PJ, Endert G, et al. Development and antitumor activity of a BCL-2 targeted single-stranded DNA oligonucleotide. Cancer Chemother Pharmacol. 2014;74:151-66.
15. Reebye V, Sætrom P, Mintz PJ, Huang K-W, Swiderski P, Peng L, et al. Novel RNA oligonucleotide improves liver function and inhibits liver carcinogenesis in vivo. Hepatology. 2014;59:216-27.
16. Xu L, Hui L, Wang S, Gong J, Jin Y, Wang Y, et al. Expression profiling suggested a regulatory role of liver-enriched transcription factors in human hepatocellular carcinoma. Cancer Res. 2001;61:3176-81.
17. Tomizawa M, Watanabe K, Saisho H, Nakagawara A, Tagawa M. Down-regulated expression of the CCAAT/enhancer binding protein alpha and beta genes in human hepatocellular carcinoma: a possible prognostic marker. Anticancer Res. 2003;23:351-4.
18. Lu G-D, Leung CH-W, Yan B, Tan CM-Y, Low SY, Aung MO, et al. C/EBPalpha is up-regulated in a subset of hepatocellular carcinomas and plays a role in cell growth and proliferation. Gastroenterology. 2010;139:632-43.
19. Nerlov C. The C/EBP family of transcription factors: a paradigm for interaction between gene expression and proliferation control. Trends Cell Biol. 2007;17:318-24.
20. Inoue Y, Inoue J, Lambert G, Yim SH, Gonzalez FJ. Disruption of hepatic C/EBPalpha results in impaired glucose tolerance and age-dependent hepatosteatosis. J Biol Chem. 2004;279:44740-8.
21. Watkins PJ, Condreay JP, Huber BE, Jacobs SJ, Adams DJ. Impaired proliferation and tumorigenicity induced by CCAAT/enhancer-binding protein. Cancer Res. 1996;56:1063-7.
22. Bader AG. miR-34-a microRNA replacement therapy is headed to the clinic. Front Genet. 2012;3:120.